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Abstract
Background: Maple syrup urine disease (MSUD) is a rare metabolic disorder, affecting the metabolism of branched
chain amino-acids (Valine, Leukine, Isoleukine). We present a rare case of rhegmatogenous retinal detachment (RRD)
in a MSUD patient.
Case presentation: We performed amino acid analysis of aqueous humour, vitreous and serum samples obtained
during surgery from a 24 year old female MSUD patient successfully operated on RRD.
Serum values for a-amino-butyric acid, valine, isoleucine, leucine, tyrosine, phenylalanine, ornithine and histidine
were low, while values for citrulline, methionine and lysine were borderline low, all attributed to the patient’s
special diet. Serum glutamate was above normal, probably due to the breakdown of glutamine to glutamate.
In the aqueous and vitreous the amino acids implicated in MSUD (Valine, Leukine Isoleukine), were within normal
range. Glutamate was absent in the vitreous and presented low levels in the aqueous. Glutamate has been
reported to play an important role in retinal damage. Elevated glutamate levels have been reported in vitreous
specimens from patients subjected to vitrectomy or buckling surgery for RRD. In MSUD, glutamate has been
implicated in the pathogenesis of brain damage. Low levels of glutamate have been observed in the cerebellum of
experimental MSUD animals, as well as postmortem brain tissue from a child that died of leucine intoxication. The
reduction was attributed to the elevation of a-ketoisocaproic which reverses the net direction of nitrogen flow. It
could be argued that this could impact on amino acid concentration in aqueous and vitreous fluids.
Conclusions: Although no definite conclusions can be drawn by this extremely rare case, the low vitreous and
aqueous levels of Glutamate is an interesting finding. Further studies are needed to provide a better insight in the
role of amino acids as neurotransmitters in the human eye in health and disease.
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Background
MSUD is a rare (1:200,000) genetic metabolic disease,
caused by a defect in branched chain ketoacid dehydro-
genase (BCKA), leading to elevated concentrations of
the branched-chain amino acids leucine, isoleucine, and
valine [1]. This enzyme is a supra enzyme complex con-
sisting of multiple copies of four distinct subunits and is
located in the inner wall of the mitochondrion. The dis-
ease has autosomal-recessive inheritance. Ocular com-
plications of untreated disease or late diagnosis include
optic atrophy, nystagmus, ophthalmoplegia, strabismus,
and cortical blindness [2].
Case presentation
A 24 year old Caucasian female was admitted to our
hospital when diagnosed with Rhegmatogenous Retinal
Detachment (RRD), on her left eye. The patient also suf-
fers from maple syrup urine disease (MSUD), for which
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she has been maintained on a special diet and
thiamine supplements, autismus (under treatment
with quetiapine, oxcarbazepine and fluvoxamine), and
ulcerative colitis (under treatment with mesalamine)
(Table 1) (Additional file 1).
Dilated fundus examination revealed an inferior retinal
detachment (3 – 8th h), macula off. The detachment had
been discovered 12 days ago and there were not any signs
of Proliferative vitreoretinopathy (PVR). The patient was
operated on successfully under general anesthesia, with
23G Vitrectomy (Constellation Vitrectomy System, Alcon
Laboratories, Texas, USA), and is under follow up for the
last four months. Apart from the successfully treated ret-
inal detachment, slit lamp biomicroscopy and fundus
examination were unremarkable on admission and during
the follow up period.
Informed consent of the custodian (mother) was ob-
tained, since the patient is mentally retarded due to
MSUD. Undiluted vitrectomy samples (approximately
0.5 ml) were obtained by a conventional three-port
closed vitrectomy technique, by manual suction at the
beginning of the vitrectomy, before opening the infusion
line of Balanced Salt Solution (BSS, Alcon Laboratories,
Texas, USA), as described earlier by Diederen et al. [3].
Aqueous humour was obtained by anterior chamber
paracentesis with 30G insulin syringe (approximately
100 μl). The serum sample was also obtained at the
same time. The aqueous and vitreous samples were
transferred to Eppendorf tubes and stored frozen, until
the time of amino acid analysis, performed at the Insti-
tute of Child Health, Department of Enzymology.
Analysis was performed by ion exchange chromatog-
raphy using the Biochrom 30 Amino Acid Analyser.
The results of the amino-acid analysis are presented in
the Table 2: Amino acid concentration in aqueous, vitre-
ous and serum, along with the findings of eight other
studies [3–10] on amino-acid concentration in ocular
fluids. This was regarded necessary, as normative data
are scarce (Table 2).
We preferred to compare to normal control values as
well as values obtained from patients with RRD from vit-
reous fluid during vitrectomy when possible, although
data from subretinal fluid (SRF) obtained during buck-
ling surgery, were available. As for the aqueous humour,
only values from normal controls were available. Norma-
tive data for serum levels were provided by the labora-
tory that performed the analysis. All values are
presented as μmol/l (μM). In the table we adopted the
standard abbreviations for amino acids. Data regarding
the patients and control groups in the aforementioned
papers are presented in brief.
The patient presented with low serum levels of several
amino-acids. Values for a-amino-butyric acid (10 μM), val-
ine (146 μM), isoleucine (52 μM), leucine (132 μM), tyro-
sine (58 μM), phenylalanine (55 μM), ornithine (22 μM)
and histidine (60 μM) were low and values for citrulline
(6 μM), methionine (23 μM) and lysine (168 μM), border-
line low. Only values of Glutamic acid (6 μM) were
detected to be above normal values in the serum. Amino-
acid concentration in the aqueous was higher than that of
the vitreous, apart from glutamine (658 μM and 627 μM
respectively), aspartic acid (3 μM and 3 μM respectively),
and citrulline (6 μM and 6 μM respectively). All three
amino acids implicated in the metabolic disorder (Valine,
Leucine, Isoleucine), were within the reported normal
ranges in the aqueous (146 μM, 132 μM, 52 μM respect-
ively) and vitreous (67 μM, 72 μM, 32 μM respectively).
Glutamate levels in were unmeasurable in the vitreous
and low in the aqueous (6 μM), while Taurine levels were
found to be close to normal limits for aqueous (46 μM)
and vitreous (21 μM).
The low serum levels of several amino-acids in the
serum were probably due to the fact that the patient has
been maintained on a strict special diet. However, values
of Glutamic acid were detected to be above normal in
the serum. This can be explained, since glutamine is
converted to glutamate on storage, and the sum of glu-
tamine + glutamate is well within the normal range. It
could be argued that the increased level of glutamate ob-
served most probably reflects the breakdown of glutam-
ine during storage.
Notably there is not an established ratio of serum to
aqueous or vitreous amino-acid concentration [11, 12].
On the contrary there has been reported that amino-acid
concentration in the aqueous is higher than that of the vit-
reous, apart from glutamine [5], which seem to be con-
firmed by the nearly identical concentrations in our
specimens (658 μM and 627 μM respectively). The serum
concentration of glutamine also lies within the same range
(599 μM) [5]. In our specimens nearly identical amino-
acid concentrations between aqueous and vitreous have
also been found for aspartic acid and citrulline [5].
All three amino acids implicated in the metabolic dis-
order (Valine, Leucine, Isoleucine), were within the re-
ported normal ranges in the aqueous and vitreous. This
is not that strange, as it has been reported that CSF
Table 1 Timeline (following the CARE Guidelines)
• Diagnosed with the aid of newborn screening and
commenced on early dietary restriction
1991
• Repeated episodes of metabolic decompensation,
usually in the context of catabolic stress associated
with non-specific illness, with subsequent brain injury
1991–2007
• Diagnosed with ulcerative colitis 2012
• Diagnosed with Rhegmatogenous Retinal Detachment 2015
• Operated on successfully under general anesthesia,
with 23G Vitrectomy
• Follow up (4 months) 2016
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Table 2 Amino acid concentration in aqueous, vitreous and serum
Amino
acid
Aqueous (μM) Vitreous (μM) Serum (μM)
MSUD Wuu et al.a Durhamb Wakabayashi
et al.c
MSUD Bertram et al.d Diederen et al.e Durhamb Honkanen
et al.f


























Pro 45 16.9 ± 15.4 16 ± 5.3 U 4 ± 5.6 101 97–297
Tau 46 29.3 ± 12 39.1 ± 11.3 22.25 ± 8.36 21 26.0 ± 7.8 22.6 ± 6.6 28.8 ± 5 11.9 ± 1.3 79(26–146) 61 27–95
Asp 3 13.4 ± 9.1 1 ± 1.5 1.81 ± 1.04 3 U 1.1 ± 0.8 6.7 ± 2.8 6.6 ± 2.5 1.7 ± 1.5 1.4 ± 1.0 3.7 ± 4.1 47(6–70) 5 2–9
Thr 158 106.7 ± 18.9 152 ± 41.4 31 73.6 ± 10.3 85.5 ± 28.4 61.8 ± 3.6 385(77–519) 130 92–180
Ser 131 111.2 ± 45.3 179 ± 38.1 89 106 ± 24.4 103.9 ± 24.4 79.2 ± 19.5 501(96–733) 99 89–165
Asn 78 27.3 ± 11.1 49.2 ± 11.5 39 24.3 ± 4.3 35.8 ± 11.6 19.5 ± 8.1 80 32–92
Glu 6 39.5 ± 18.8 12 ± 3.4 2.98 ± 1.12 U 13.4 ±
11.9
1.7 ± 0.8 16.6 ± 5.6 13.1 ± 5.2 14.5 ± 11 5.2 ± 2.3 3.8 ± 5.1 20(10–82) 96 6–62
Gln 658 95.9 ± 68.9 717 ± 134 627 1192.9 ± 404.4 3386(714–4698) 599 466–798
Gly 71 7 ± 3.2 16.7 ± 3.5 5 U 4 ± 2.7 42.5 ± 32.0 49.4 ± 36.3 8.7 ± 2.6 8.5 ± 2.5 10.2 ± 6.2 56(15–196) 256 147–299
Ala 227 182.7 ± 91.4 294 ± 66.1 105.98 ± 9.88 85 U 88.4 ± 35 126 ± 15.6 159.5 ± 54.9 31.8 ± 10.6 896(125–1842) 241 146–494
Cit 6 3.8 ± 6.6 9.8 ± 4.8 6 8.3 ± 1.6 9(5–27) 18 19–47
Abu 10 10.6 ± 5.7 31.4 ± 7.8 U 14.4 ± 1.7 9 15–35
Val 146 281.2 ±
180.6
388 ± 84.5 67 U 112 ± 4.4 174 ± 41.3 87.5 ± 6.5 909(140–1277) 95 179–335
Cys 9 7.9 ± 1.7 11.2 ± 3.5 4 6.5 ± 6 42 24–54
Met 23 18.8 ± 8.6 44.4 ± 9.9 13 24.7 ± 5 22.3 ± 8.1 13.2 ± 3.2 84(12–133) 13 13–37
Ile 52 72.2 ± 26.2 79.8 ± 6.9 32 U 28.3 ± 12.0 37.6 ± 3.4 37.9 ± 11.6 32.8 ± 5.1 220(39–317) 27 46–90
Leu 132 169.5 ± 72.2 192 ± 39.6 72 U 63.5 ± 21.9 96.1 ± 20.5 89.7 ± 28.4 76.5 ± 5.3 584(93–737) 88 113–205
Tyr 58 79.2 ± 37.6 123 ± 16.5 32 U 31.9 ± 3.7 51.8 ± 12.3 58.2 ± 18.8 41.1 ± 6.3 365(58–399) 29 37–77
Phe 55 97.7 ± 30.3 119 ± 14 28 U 31.7 ± 11 56.8 ± 13.6 44.4 ± 14.2 43.3 ± 1.9 356(66–469) 29 46–74
Orn 22 15 ± 3.4 25.3 ± 4.6 15 16 ± 1.1 13.6 ± 0.9 42 55–135













Table 2 Amino acid concentration in aqueous, vitreous and serum (Continued)
His 60 47.6 ± 9.5 77.9 ± 12.7 29 40.7 ± 13.8 38.4 ± 10.0 62 72–108
Trp 36 U 31.9 ± 10 U 18.3 ± 7 7.4 ± 1.2 24 n/a
Arg 100 29.2 ± 13 133 ± 26 66 U 52.7 ± 46.0 71.9 ± 10.2 62.3 ± 10.5 46 28–96
MSUD maple syrup urine disease-i.e., our patient, μM μmol/l, U unmeasurable; empty cells refer to not available data
MH macular hole, ERM epiretinal membrane, a.c. anterior chamber, RRD rhegmatogenous retinal detachment, TRD tractional retinal detachment, PPV pars plana vitrectomy, LAB(normal) normal reference values
provided by the laboratory that performed the amino acid analysis
Data regarding previous studies
a Wuu et al. [4]: Controls: Aqueous: n = 3 (ophthalmological emergency operations - Chinese population)
bDurham [5]: Controls: Aqueous: normal eyes, a.c. paracentesis (n = 9, mean age 28y (2.5–77). Vitreous: procedure with vitreous loss (n = 3, Marfan/cataract/enucleation, age = 40/21/35 y)
c Wakabayashi et al. [6]: Controls: cataract without other ocular disease (n = 9, age 66.1 ± 12.8 y.)
d Bertram et al. [7]: PPV for RRD (n = 5, age =63.8 ± 15.5 y., duration 52.4 ± 65.4 days). Controls: vitrectomy for MH (n = 7) or ERM (n = 3) (age =66.1 ± 12.1 y.)
e Diederen et al. [3]: PPV for primary retinal detachment (n = 114, age = 58.2 ± 15.1 y., duration 43.6 ± 72.1 days). Controls: PPV for MH or ERM (n = 52, age = 51.3 ± 14.0 y.)
f Honkanen et al. [8]: Controls: PPV for MH (n = 10 [2 RRD]), ERM(n = 6[2 TRD]), MH and ERM (n = 1). Total number of eyes: (n = 17, age = 68 ± 14 y.)
g Asensio et al. [9]: 64 eyes with RRD n = (45), MH (n = 5) and ERM (n = 14). Age = 67.7 ± 14.2 y. [No statistically significant difference neither between groups, nor regarding age]













amino acid concentrations do not reflect serum concen-
tration, and blood–brain barrier has its equivalent in the
eye in the form of blood-aqueous and blood-retina bar-
riers [13].
On the other hand, presumably important factors that
determine the concentration of amino acids in aqueous
and vitreous are not yet clear. The active efflux of amino
acids in the aqueous [14, 15], combined with the turn-
over rate of the aqueous and the sink effect of the vitre-
ous itself [15], as well as the variability of amino acid
concentration in the normal vitreous comprise a dy-
namic equilibrium system.
Another interesting aspect of our results is the absence
of glutamate in the vitreous, and the low levels in the
aqueous. Glutamate has been reported to play an im-
portant role in retinal damage, and elevated glutamate
levels have been reported in vitreous specimens from pa-
tients subjected to vitrectomy for RRD. [3, 7] In RRD pa-
tients treated with scleral buckle, elevated levels of
glutamate in Subretinal fluid (SRF) have also been re-
ported. In these patients SRF glutamate levels seem to
rise in parallel with the duration of the detachment [10].
Elevated glutamate levels in the aqueous have also been
reported in cases of retinal artery occlusion [6], and in
glaucoma patients [8].
Glutamate is the main excitatory neurotransmitter in
the central nervous system (CNS) and the retina [16],
and is constantly released from the synapses of photore-
ceptors but also bipolar and amacrine cells, in a Ca+2-
dependent manner. It also seems that there is a Ca+2-in-
dependent mechanism under stress conditions (hypoxia),
by reversal of the plasma membrane uptake carrier. Glu-
tamate is normally removed from the extracellular space
by the glutamate/aspartate transporter system, by neur-
onal and glial cells. Failure to remove glutamate from
the extracellular space, causes an increase in glutamate
concentration and leads to overstimulation of N-methyl-
D-aspartate receptor, leading to Ca+2 influx into cells.
The increased intracellular Ca+2 leads to the production
of nitric oxide (NO), that interacts with oxygen to form
extremely toxic free radicals resulting in retinal neuronal
death [17, 18]. Regarding retinal detachment, an acute
efflux of neuronal glutamate, caused by injury-mediated
acute depolarization and release of glutamate vesicles
may also trigger the above mechanism and lead to exci-
totoxic cell death in the detached retina [18, 19].
In MSUD glutamate has been implicated in the patho-
genesis of brain damage.
Low levels of glutamate have been observed in the
cerebellum of experimental MSUD animals [20, 21] as
well as postmortem brain tissue from a child that died
of leucine intoxication [22]. The reduction was sug-
gested to result from the elevation of a ketoisocaproic
which reverses the net direction of nitrogen flow. It
could be argued that this could impact on amino acid
concentration in aqueous and vitreous fluids. Although a
correlation was found between increased vitreous glu-
tamate and a lower pre-operative visual acuity, this was
not the case regarding visual outcome.
Diederen et al. [3] detected that apart from glutamate,
taurine levels were also increased in RRD. In our patient
taurine levels were found to be within normal limits.
Taurine is one of the most abundant amino acids in the
brain and retina, although it is one of the few amino
acids not incorporated into proteins. In the retina, tau-
rine is critical for photoreceptor development and acts
as a cytoprotectant against stress-related neuronal dam-
age [23].
Conclusions
It is obvious that no definite conclusions regarding
amino acid concentration in aqueous and vitreous of
MSUD patients with RRD can be drawn by this case.
We present our data not only because this is a rare case
of RRD in a MSUD patient (no other case has been re-
ported till now according to our best knowledge), but
also to draw attention to rare diseases and metabolic dis-
orders with ophthalmological complications that, if stud-
ied adequately, may provide useful data for the patients
care, as well as a better insight in the role of amino acids
as neurotransmitters in the human eye.
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